Advanced Biomed Inc. Common Stock (ADVB) - Total Liabilities
Based on the latest financial reports, Advanced Biomed Inc. Common Stock (ADVB) has total liabilities worth $44.94K USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore ADVB year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Advanced Biomed Inc. Common Stock - Total Liabilities Trend (2021–2025)
This chart illustrates how Advanced Biomed Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data. See Advanced Biomed Inc. Common Stock (ADVB) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
Advanced Biomed Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of Advanced Biomed Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
FGI Industries Ltd
NASDAQ:FGI
|
USA | $55.00 Million |
|
XTL Biopharmaceuticals Ltd ADR
NASDAQ:XTLB
|
USA | $3.12 Million |
|
Energy Development Company Limited
NSE:ENERGYDEV
|
India | Rs1.83 Billion |
|
Wahana Pronatural
JK:WAPO
|
Indonesia | Rp98.34 Billion |
|
NEXE Innovations Inc
V:NEXE
|
Canada | CA$2.85 Million |
|
Talisman Mining Ltd
AU:TLM
|
Australia | AU$1.00 Million |
|
Renoworks Software Inc
V:RW
|
Canada | CA$2.31 Million |
|
BRADDA HEAD LITHIUM O.N.
F:8CD1
|
Germany | €73.64K |
Liability Composition Analysis (2021–2025)
This chart breaks down Advanced Biomed Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see ADVB market cap.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.38 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.16 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.13 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Advanced Biomed Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Advanced Biomed Inc. Common Stock (2021–2025)
The table below shows the annual total liabilities of Advanced Biomed Inc. Common Stock from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | $3.03 Million | +8.50% |
| 2024-06-30 | $2.80 Million | -15.10% |
| 2023-06-30 | $3.29 Million | +2.25% |
| 2022-06-30 | $3.22 Million | +10592.98% |
| 2021-06-30 | $30.13K | -- |
About Advanced Biomed Inc. Common Stock
Advanced Biomed Inc., an investment holding company, engages in the research and development of microfluidic biochip technologies for precision oncology detection, diagnosis, and treatment in Taiwan. Its devices include A+Pre, an automated sample preparation system that enables pre-concentration of diluted blood samples; AC-1000, a rare cell device to solve the problem of detection of hypercoagul… Read more